Beyond the Waiting Room: Can Shared Care Make Hepatitis C Treatment Faster?

There’s a simple beauty in a river that finds a new course — the water doesn’t rush, but over time, the landscape shifts gently, quietly, until what was once detour becomes the main channel. In the world of healthcare, the story of hepatitis C treatment is beginning to trace such a curve: shifting from narrow specialist pathways into the broader flow of primary care, carrying the promise of faster treatment access for many more people.

For years, curing hepatitis C meant a journey through specialists: appointments, letters of referral, waiting lists, insurance authorizations and pharmacy steps that could stretch into months before treatment began. But recently, an evolution in how we deliver care has taken root. Because direct-acting antiviral medications now require less frequent monitoring and fewer adverse effects, they can be managed safely outside hospital walls, right where many patients first seek help — in their family medicine clinics.

One urban family medicine residency clinic in Columbus, Ohio, decided to explore this new path. Beginning in mid-2022, an interdisciplinary team — bringing together a physician champion, a pharmacist and supportive office staff — set out to streamline access to care. They shared administrative tasks like prior authorizations and followed patients closely, with pharmacists helping to ensure adherence once prescriptions were written. In doing so, they transformed a six-month wait into one that’s often less than two.

This approach mirrors what researchers outside clinical practice have been learning. In a randomized trial conducted in Australia and New Zealand known as the Prime Study, providing hepatitis C therapy within primary care settings significantly increased both treatment uptake and cure rates compared with typical hospital-based specialist care. Meanwhile, community programs that engage primary care providers — supported by tertiary centers — show high rates of treatment initiation and completion, with low failure rates, suggesting that support and training can make a real difference on the ground.

These trends align with global public health guidance, which now calls for simplified service delivery and task-sharing — expanding testing, care, and treatment into primary care, harm-reduction programs, and other accessible sites. In the gentle weave of these changes lies a larger narrative: care that meets people where they are, rather than asking them to travel further down a labyrinth of appointments.

At its heart, this isn’t just about shortening a wait or lifting an administrative cloud. It’s about making cure possible sooner, so that the lives being lived beyond a hepatitis C diagnosis are not defined by delay. It’s about bringing treatment into spaces where healing feels human — familiar, immediate, and attainable.

In recent evaluations, interdisciplinary primary care teams have succeeded in doing exactly that: reducing the time from diagnosis to treatment, increasing treatment uptake, and enabling more patients to complete antiviral therapy without the prolonged waits that were once all too common

AI Image Disclaimer (rotated wording) Illustrations were produced with AI and serve as conceptual depictions.

Sources News-Medical Mirage News Clinical Infectious Diseases (Prime Study) BMC Public Health World Health Organization Guidance